Billiontoone SVP of Laboratory Operations John Roderick Ten Bosch Disposes of 1,416 Common Shares for $169,920

Billiontoone Study Finds Northstar Response Ctdna Test Outperforms Imaging in Predicting Immunotherapy Outcomes

Billiontoone Initiated at Buy by Guggenheim

BillionToOne price target raised to $125 from $120 at Guggenheim

Billiontoone Chief Product Officer Sakakibara Shan Riku Disposes of 8,000 Common Shares Worth $880,000

BillionToOne CTO David Tsao disposes of USD 1.51 million in common shares

BillionToOne Stockholders Back Directors and Auditor at Meeting

Billiontoone shareholders elect two directors at annual meeting

BillionToOne Chief Product Officer Sakakibara Shan Riku disposes of 8,000 common shares worth $785,800

BillionToOne SVP Sales Nancy JoAnn Johnson sells $1.39 million Class A shares

BillionToOne CEO and Chairman Oguzhan Atay disposes of 26,171 common shares for $2.55 million

BillionToOne publishes immunotherapy ctDNA monitoring research presentation

BillionToOne to Participate in the William Blair 46th Annual Growth Stock Conference

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY), BillionToOne, Inc. Class A (BLLN) and Solventum Corporation (SOLV)

BillionToOne Is Maintained at Buy by Guggenheim

Stock Track | BillionToOne Soars 6.12% in Pre-market After Guggenheim Raises Price Target to $120

U.S. RESEARCH ROUNDUP-Aecom, Humana, Mosaic